The shifts in microbial communities were linked to therapeutic outcomes, where AMPs elevated beneficial bacteria like Roseburia, enhancing gut health and reducing obesity-related inflammation. This evidence concerns the gene ADSL and obesity due to melanocortin 4 receptor deficiency.